European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer

Cancer Treat Rep. 1987 Dec;71(12):1317-8.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Carcinoma / drug therapy*
  • Dose-Response Relationship, Drug
  • Doxorubicin / administration & dosage*
  • Doxorubicin / adverse effects
  • Drug Evaluation
  • Epirubicin
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis
  • Prostatic Neoplasms / drug therapy*

Substances

  • Epirubicin
  • Doxorubicin